{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:38:34Z","timestamp":1791923914245,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is limited evidence on the blood pressure (BP)-lowering effect of esaxerenone on home BP, including nighttime BP. Using two newly developed nocturnal home BP monitoring devices (brachial and wrist), this multicenter, open-label, prospective study investigated the nighttime home BP-lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension being treated with an angiotensin receptor blocker (ARB) or calcium-channel blocker (CCB). In total, 101 patients were enrolled. During the 12-week study period, change in nighttime home systolic\/diastolic BP from baseline to end of treatment measured by the brachial device was \u221212.9\/\u22125.4\u2009mmHg in the total population and \u221216.2\/\u22126.6 and \u221210.0\/\u22124.4\u2009mmHg in the ARB and CCB subcohorts, respectively (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). For the wrist device, the change was \u221211.7\/\u22125.4\u2009mmHg in the total population and \u221214.6\/\u22126.2 and \u22128.3\/\u22124.5\u2009mmHg in each subcohort, respectively (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Similar significant reductions were shown for morning and bedtime home BP and office BP. Urinary albumin-to-creatinine ratio, N-terminal pro-brain natriuretic peptide, and cardio-ankle vascular index improved in the total population and each subcohort. Incidences of treatment-emergent adverse events (TEAEs) and drug-related TEAEs were 38.6% and 16.8%, respectively; most were mild or moderate. The most frequent drug-related TEAEs were associated with serum potassium elevation (hyperkalemia, 9.9%; blood potassium increased, 3.0%); however, no new safety concerns were raised. Esaxerenone was effective in lowering nighttime home BP as well as morning and bedtime home BP and office BP, safe, and showed organ-protective effects in patients with uncontrolled nocturnal hypertension. Caution is warranted regarding elevated serum potassium levels.<\/jats:p>","DOI":"10.1038\/s41440-023-01292-0","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T09:02:38Z","timestamp":1683882158000},"page":"1782-1794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study"],"prefix":"10.1038","volume":"46","author":[{"given":"Kazuomi","family":"Kario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Shiraiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Kaneshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Shiosakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"1292_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1161\/HYPERTENSIONAHA.121.17440","volume":"78","author":"K Kario","year":"2021","unstructured":"Kario K, Williams B. Nocturnal hypertension and heart failure: mechanisms, evidence, and new treatments. Hypertension. 2021;78:564\u201377.","journal-title":"Hypertension."},{"key":"1292_CR2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1161\/HYPERTENSIONAHA.118.10971","volume":"71","author":"K Kario","year":"2018","unstructured":"Kario K. Nocturnal hypertension: new technology and evidence. Hypertension. 2018;71:997\u20131009.","journal-title":"Hypertension."},{"key":"1292_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41440-022-01087-9","volume":"46","author":"K Kario","year":"2023","unstructured":"Kario K, Tomitani N, Nishizawa M, Harada N, Kanegae H, Hoshide S. Concept, study design, and baseline blood pressure control status of the nationwide prospective HI\u2013JAMP study using multisensor ABPM. Hypertens Res. 2023;46:357\u201367.","journal-title":"Hypertens Res"},{"key":"1292_CR4","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1038\/s41440-021-00745-8","volume":"44","author":"N Tomitani","year":"2021","unstructured":"Tomitani N, Hoshide S, Kario K. Accurate nighttime blood pressure monitoring with less sleep disturbance. Hypertens Res. 2021;44:1671\u201373.","journal-title":"Hypertens Res"},{"key":"1292_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/jch.13499","volume":"21","author":"M Kuwabara","year":"2019","unstructured":"Kuwabara M, Harada K, Hishiki Y, Kario K. Validation of two watch-type wearable blood pressure monitors according to the ANSI\/AAMI\/ISO81060-2:2013 guidelines: Omron HEM-6410T-ZM and HEM-6410T-ZL. J Clin Hypertens. 2019;21:853\u20138.","journal-title":"J Clin Hypertens"},{"key":"1292_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/jch.14179","volume":"23","author":"K Kario","year":"2021","unstructured":"Kario K, Tomitani N, Iwashita C, Shiga T, Kanegae H. Simultaneous self-monitoring comparison of a supine algorithm-equipped wrist nocturnal home blood pressure monitoring device with an upper arm device. J Clin Hypertens. 2021;23:793\u2013801.","journal-title":"J Clin Hypertens"},{"key":"1292_CR7","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1111\/jch.14342","volume":"23","author":"N Tomitani","year":"2021","unstructured":"Tomitani N, Kanegae H, Kario K. Reproducibility of nighttime home blood pressure measured by a wrist-type nocturnal home blood pressure monitoring device. J Clin Hypertens. 2021;23:1872\u201378.","journal-title":"J Clin Hypertens"},{"key":"1292_CR8","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s41440-021-00667-5","volume":"44","author":"S Hoshide","year":"2021","unstructured":"Hoshide S, Kanegae H, Kario K. Nighttime home blood pressure as a mediator of N-terminal pro-brain natriuretic peptide in cardiovascular events. Hypertens Res. 2021;44:1138\u201346.","journal-title":"Hypertens Res"},{"key":"1292_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1161\/HYPERTENSIONAHA.120.14790","volume":"76","author":"T Fujiwara","year":"2020","unstructured":"Fujiwara T, Hoshide S, Kanegae H, Kario K. Cardiovascular event risks associated with masked nocturnal hypertension defined by home blood pressure monitoring in the J-HOP Nocturnal Blood Pressure Study. Hypertension. 2020;76:259\u201366.","journal-title":"Hypertension."},{"key":"1292_CR10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1161\/HYPERTENSIONAHA.119.14344","volume":"76","author":"GG Mokwatsi","year":"2020","unstructured":"Mokwatsi GG, Hoshide S, Kanegae H, Fujiwara T, Negishi K, Schutte AE, et al. Direct comparison of home versus ambulatory defined nocturnal hypertension for predicting cardiovascular events: the Japan Morning Surge-Home Blood Pressure (J-HOP) Study. Hypertension. 2020;76:554\u201361.","journal-title":"Hypertension."},{"key":"1292_CR11","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/HYPERTENSIONAHA.118.12740","volume":"73","author":"K Kario","year":"2019","unstructured":"Kario K, Kanegae H, Tomitani N, Okawara Y, Fujiwara T, Yano Y, et al. Nighttime blood pressure measured by home blood pressure monitoring as an independent predictor of cardiovascular events in general practice. Hypertension. 2019;73:1240\u201348.","journal-title":"Hypertension."},{"key":"1292_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/ggi.13276","volume":"18","author":"T Ishida","year":"2018","unstructured":"Ishida T, Oh A, Hiroi S, Shimasaki Y, Tsuchihashi T. Current use of antihypertensive drugs in Japanese patients with hypertension: analysis by age group. Geriatr Gerontol Int. 2018;18:899\u2013906.","journal-title":"Geriatr Gerontol Int"},{"key":"1292_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ajh.2011.245","volume":"25","author":"H Shibata","year":"2012","unstructured":"Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514\u201323.","journal-title":"Am J Hypertens"},{"key":"1292_CR14","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","volume":"42","author":"H Rakugi","year":"2019","unstructured":"Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res. 2019;42:1932\u201341.","journal-title":"Hypertens Res"},{"key":"1292_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41440-021-00756-5","volume":"45","author":"K Kario","year":"2022","unstructured":"Kario K, Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S. Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes. Hypertens Res. 2022;45:97\u2013105.","journal-title":"Hypertens Res"},{"key":"1292_CR16","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/s41440-019-0270-2","volume":"42","author":"H Itoh","year":"2019","unstructured":"Itoh H, Ito S, Rakugi H, Okuda Y, Nishioka S. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertens Res. 2019;42:1572\u201381.","journal-title":"Hypertens Res"},{"key":"1292_CR17","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol. 2020;15:1715\u201327.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1292_CR18","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s10157-021-02075-y","volume":"25","author":"S Ito","year":"2021","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study. Clin Exp Nephrol. 2021;25:1070\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"1292_CR19","first-page":"5158","volume":"39","author":"HA Uchida","year":"2022","unstructured":"Uchida HA, Nakajima H, Hashimoto M, Nakamura A, Nunoue T, Murakami K, et al. Efficacy and safety of esaxerenone in hypertensive patients with diabetic kidney disease: a multicenter, open-label, prospective study. Adv Ther. 2022;39:5158\u201375.","journal-title":"Adv Ther"},{"key":"1292_CR20","unstructured":"Daiichi Sankyo Co., Ltd. Highlights of prescribing information Esaxerenone. ver. 5. 2022. https:\/\/www.info.pmda.go.jp\/go\/pack\/2149049F1027_1_07\/?view=frame&style=XML&lang=ja."},{"key":"1292_CR21","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u201381.","journal-title":"Hypertens Res"},{"key":"1292_CR22","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jacc.2016.01.037","volume":"67","author":"K Kario","year":"2016","unstructured":"Kario K, Saito I, Kushiro T, Teramukai S, Tomono Y, Okuda Y, et al. Morning home blood pressure is a strong predictor of coronary artery disease: the HONEST study. J Am Coll Cardiol. 2016;67:1519\u201327.","journal-title":"J Am Coll Cardiol"},{"key":"1292_CR23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/ajh\/hpaa155","volume":"34","author":"K Kario","year":"2021","unstructured":"Kario K, Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, et al. Effect of the nonsteroidal mineralocorticoid receptor blocker, esaxerenone, on nocturnal hypertension: a post hoc analysis of the ESAX-HTN Study. Am J Hypertens. 2021;34:540\u201351.","journal-title":"Am J Hypertens"},{"key":"1292_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension. 2020;75:51\u20138.","journal-title":"Hypertension."},{"key":"1292_CR25","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1007\/s12325-022-02393-x","volume":"40","author":"S Ito","year":"2023","unstructured":"Ito S, Okuda Y, Sugimoto K. Factors associated with the antihypertensive effect of esaxerenone and serum potassium elevation: a pooled analysis of seven phase III studies. Adv Ther. 2023;40:1242\u201366.","journal-title":"Adv Ther"},{"key":"1292_CR26","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/j.1532-5415.2010.02905.x","volume":"58","author":"PA Kithas","year":"2010","unstructured":"Kithas PA, Supiano MA. Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension. J Am Geriatr Soc. 2010;58:1327\u201332.","journal-title":"J Am Geriatr Soc"},{"key":"1292_CR27","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3390\/jcm8101671","volume":"8","author":"B Krasi\u0144ska","year":"2019","unstructured":"Krasi\u0144ska B, Cofta S, Szczepaniak-Chiche\u0142 L, Rzymski P, Trafas T, Paluszkiewicz L, et al. The effects of eplerenone on the circadian blood pressure pattern and left ventricular hypertrophy in patients with obstructive sleep apnea and resistant hypertension-a randomized, controlled trial. J Clin Med. 2019;8:1671.","journal-title":"J Clin Med"},{"key":"1292_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/1470320310390404","volume":"12","author":"Y Yano","year":"2011","unstructured":"Yano Y, Hoshide S, Tamaki N, Nagata M, Sasaki K, Kanemaru Y, et al. Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study. J Renin Angiotensin Aldosterone Syst. 2011;12:340\u20137.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"1292_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41371-020-0377-6","volume":"35","author":"N Wan","year":"2021","unstructured":"Wan N, Rahman A, Nishiyama A. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease. J Hum Hypertens. 2021;35:148\u201356.","journal-title":"J Hum Hypertens"},{"key":"1292_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41440-022-01008-w","volume":"46","author":"Y Okuda","year":"2023","unstructured":"Okuda Y, Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, et al. The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial. Hypertens Res. 2023;46:437\u201344.","journal-title":"Hypertens Res"},{"key":"1292_CR31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/jch.12321","volume":"16","author":"S Hoshide","year":"2014","unstructured":"Hoshide S, Nagai M, Yano Y, Ishikawa J, Eguchi K, Kario K. Association of high-sensitivity cardiac troponin T and N-terminal pro-brain-type natriuretic peptide with left ventricular structure: J-HOP study. J Clin Hypertens. 2014;16:354\u201361.","journal-title":"J Clin Hypertens"},{"key":"1292_CR32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/jch.12500","volume":"17","author":"K Kario","year":"2015","unstructured":"Kario K, Hoshide S, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S, et al. Sleep blood pressure self-measured at home as a novel determinant of organ damage: Japan morning surge home blood pressure (J-HOP) study. J Clin Hypertens. 2015;17:340\u20138.","journal-title":"J Clin Hypertens"},{"key":"1292_CR33","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2169\/internalmedicine.54.3427","volume":"54","author":"T Shibata","year":"2015","unstructured":"Shibata T, Tsutsumi J, Hasegawa J, Sato N, Murashima E, Mori C, et al. Effects of add-on therapy consisting of a selective mineralocorticoid receptor blocker on arterial stiffness in patients with uncontrolled hypertension. Intern Med. 2015;54:1583\u20139.","journal-title":"Intern Med"},{"key":"1292_CR34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7:128\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1292_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","volume":"7","author":"J Coresh","year":"2019","unstructured":"Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7:115\u201327.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1292_CR36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0140-6736(09)61378-7","volume":"374","author":"CE Jackson","year":"2009","unstructured":"Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009;374:543\u201350.","journal-title":"Lancet."},{"key":"1292_CR37","first-page":"100553","volume":"29","author":"H Rudolf","year":"2020","unstructured":"Rudolf H, M\u00fcgge A, Trampisch HJ, Scharnagl H, M\u00e4rz W, Kara K. NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: the getABI-study. Int J Cardiol Heart Vasc. 2020;29:100553.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"1292_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1620\/tjem.221.175","volume":"221","author":"S Yamanouchi","year":"2010","unstructured":"Yamanouchi S, Kudo D, Endo T, Kitano Y, Shinozawa Y. Blood N-terminal proBNP as a potential indicator of cardiac preload in patients with high volume load. Tohoku J Exp Med. 2010;221:175\u201380.","journal-title":"Tohoku J Exp Med"},{"key":"1292_CR39","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1177\/2047487316683070","volume":"24","author":"PY Courand","year":"2017","unstructured":"Courand PY, Harbaoui B, B\u00e8cle C, Mouly-Bertin C, Lantelme P. Plasma NT-proBNP mirrors the deleterious cardiovascular and renal continuum in hypertension. Eur J Prev Cardiol. 2017;24:452\u20139.","journal-title":"Eur J Prev Cardiol"},{"key":"1292_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/jch.13425","volume":"21","author":"K Matsushita","year":"2019","unstructured":"Matsushita K, Ding N, Kim ED, Budoff M, Chirinos JA, Fernhall B, et al. Cardio-ankle vascular index and cardiovascular disease: systematic review and meta-analysis of prospective and cross-sectional studies. J Clin Hypertens. 2019;21:16\u201324.","journal-title":"J Clin Hypertens"},{"key":"1292_CR41","doi-asserted-by":"publisher","first-page":"e020103","DOI":"10.1161\/JAHA.120.020103","volume":"10","author":"T Miyoshi","year":"2021","unstructured":"Miyoshi T, Ito H, Shirai K, Horinaka S, Higaki J, Yamamura S, et al. Predictive value of the cardio-ankle vascular index for cardiovascular events in patients at cardiovascular risk. J Am Heart Assoc. 2021;10:e020103.","journal-title":"J Am Heart Assoc"},{"key":"1292_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41440-020-00569-y","volume":"44","author":"H Rakugi","year":"2021","unstructured":"Rakugi H, Yamakawa S, Sugimoto K. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone. Hypertens Res. 2021;44:371\u201385.","journal-title":"Hypertens Res"},{"key":"1292_CR43","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","volume":"33","author":"S Ito","year":"2019","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S.\u00a0Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study. J Hum Hypertens. 2019;33:542\u201351.","journal-title":"J Hum Hypertens"},{"key":"1292_CR44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/jch.14440","volume":"24","author":"K Kario","year":"2022","unstructured":"Kario K, Chia YC, Siddique S, Turana Y, Li Y, Chen CH, et al. Seven-action approaches for the management of hypertension in Asia\u2014The HOPE Asia network. J Clin Hypertens. 2022;24:213\u201323.","journal-title":"J Clin Hypertens"},{"key":"1292_CR45","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1161\/HYPERTENSIONAHA.117.10238","volume":"71","author":"K Kario","year":"2018","unstructured":"Kario K, Chen CH, Park S, Park CG, Hoshide S, Cheng HM, et al. Consensus document on improving hypertension management in Asian patients, taking into account Asian characteristics. Hypertension. 2018;71:375\u201382.","journal-title":"Hypertension."},{"key":"1292_CR46","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/jch.14555","volume":"24","author":"K Kario","year":"2022","unstructured":"Kario K, Wang JG, Chia YC, Wang TD, Li Y, Siddique S, et al. The HOPE Asia network 2022 up-date consensus statement on morning hypertension management. J Clin Hypertens. 2022;24:1112\u201320.","journal-title":"J Clin Hypertens"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01292-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01292-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01292-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T23:06:10Z","timestamp":1688511970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01292-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1038\/s41440-023-01292-0","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"30 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KK has received research funding from A&D Co., Ltd., Otsuka Holdings Co., Ltd., OMRON HEALTHCARE Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Taisho Pharma Co., Ltd., Teijin Pharma Ltd., Fukuda Lifetech Co., Ltd., and Fukuda Denshi Co., Ltd.; scholarships or donations from Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and Mochida Pharmaceutical Co., Ltd; and is an editorial board member of Hypertension Research; however, Hypertension Research automatically selects a Deputy Editor when papers from members of the editorial board are submitted, and he is completely independent of the review process. M Nishizawa has received honoraria and fees for promotional materials from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., and Otsuka Pharmaceutical Co., Ltd. TY has received honoraria and fees for promotional materials from Daiichi Sankyo Co., Ltd. TT, K Shiosakai, and K Sugimoto are employees of Daiichi Sankyo Co., Ltd. The other authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}